Survival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer

被引：0
|
作者：
Kimmick, G. G.
Camacho, F.
Wei, W.
Balkrishnan, R.
Anderson, R.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Penn State Coll Med, Hershey, PA USA
[3] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[4] Ohio State Univ, Sch Publ Hlth, Columbus, OH 43210 USA
[5] Roche, Nutley, NJ USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：374S / 374S
页数：1
相关论文
共 50 条
  • [31] Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer
    Hirofumi Mukai
    Yukari Uemura
    Hiromitsu Akabane
    Takanori Watanabe
    Youngjin Park
    Masato Takahashi
    Yoshiaki Sagara
    Reiki Nishimura
    Tsutomu Takashima
    Tomomi Fujisawa
    Yasuo Hozumi
    Takuya Kawahara
    British Journal of Cancer, 2021, 125 : 1217 - 1225
  • [32] First-line Bevacizumab plus Taxane-based Chemotherapy for Metastatic Breast Cancer: Cost-minimisation Analysis
    Nerich, Virginie
    Bazan, Fernando
    Compagnat, Fanny
    Dobi, Erion
    Villanueva, Cristian
    Chaigneau, Loic
    Perrin, Sophie
    Voidey, Aline
    Pivot, Xavier
    Limat, Samuel
    ANTICANCER RESEARCH, 2012, 32 (08) : 3547 - 3552
  • [33] First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis
    Nerich, Virginie
    Chelly, Jennifer
    Montcuquet, Philippe
    Chaigneau, Loic
    Villanueva, Cristian
    Fiteni, Frederic
    Meneveau, Nathalie
    Perrin, Sophie
    Voidey, Aline
    Monnot, Tess
    Pivot, Xavier
    Limat, Samuel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (05) : 362 - 368
  • [34] First-line Bevacizumab Plus Taxane-based Chemotherapy for Metastatic Breast Cancer (mBC): Cost Minimisation Analysis
    Compagnat, F.
    Nerich, V.
    Bazan, F.
    Voidey, A.
    Villanueva, C.
    Dobi, E.
    Thiery-Vuillemin, A.
    Chaigneau, L.
    Pivot, X.
    Limat, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S260 - S260
  • [35] First-line chemotherapy with or without biologic agents for metastatic breast cancer
    Andreetta, Claudia
    Minisini, Alessandro M.
    Miscoria, Manuela
    Puglisi, Fabio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 76 (02) : 99 - 111
  • [36] Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer
    Baltali, E
    Özisik, Y
    Güler, N
    Firat, D
    Altundag, K
    TUMORI, 2001, 87 (01) : 18 - 19
  • [37] WEEKLY EPIRUBICIN AND DOCETAXEL AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER
    D'Ottavio, A.
    Vaccaro, A.
    Belli, F.
    Nunziata, C.
    Meliffi, L.
    Moscetti, L.
    Barduagni, M.
    Sperduti, I.
    Gamucci, T.
    ANNALS OF ONCOLOGY, 2004, 15 : 19 - 19
  • [38] Outcomes of first-line chemotherapy for visceral crisis in metastatic breast cancer
    Andrade, Matheus de Oliveira
    Felix, Vitor Hugo
    Bonadio, Renata Colombo
    Testa, Laura
    CANCER RESEARCH, 2024, 84 (09)
  • [39] A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer
    Lueck, Hans-Joachim
    Luebbe, Kristina
    Bischoff, Joachim
    Maass, Nicolai
    Feisel, Gabriele
    Tome, Oliver
    Janni, Wolfgang
    Aydogdu, Mustafa
    Neuhoeffer, Tanja
    Ober, Angelika
    Aktas, Bahriye
    Park-Simon, Tjoung-Won
    Schumacher, Claudia
    Hoeffkes, Heinz-Gert
    Illmer, Thomas
    Wagner, Harald
    Mehta, Keyur
    Nekljudova, Valentina
    Loibl, Sibylle
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (02) : 385 - 385
12345